Review: Gimme five: Future challenges in multiple sclerosis. ECTRIMS Lecture 2009

Multiple Sclerosis

Volumn 16, Issue 1, 2010, Pages 3-14

  Hohlfeld, Reinhard ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biomarker; Immunotherapy; Multiple sclerosis; Neuroprotection

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CLADRIBINE; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID; GLATIRAMER; INTERLEUKIN 17; LAQUINIMOD; MYELIN BASIC PROTEIN; NATALIZUMAB; T LYMPHOCYTE RECEPTOR; TERIFLUNOMIDE; NEUROPROTECTIVE AGENT;

ALLERGIC ENCEPHALOMYELITIS; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; DEMYELINATION; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; GENETIC ENGINEERING; HUMAN; LYMPHOCYTE MIGRATION; MEDICAL ETHICS; MOLECULAR IMAGING; MULTIPLE SCLEROSIS; NERVE REGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PROTEOMICS; REGULATORY T LYMPHOCYTE; REVIEW; RISK BENEFIT ANALYSIS; TH1 CELL; TH17 CELL; TH2 CELL; TRANSCRIPTOMICS; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; ANIMAL; ARTICLE; EUROPE; GENETICS; NERVOUS SYSTEM; PATHOLOGY; PERSONALIZED MEDICINE; RISK ASSESSMENT;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ETHICS, MEDICAL; EUROPE; GENETIC ENGINEERING; HUMANS; INDIVIDUALIZED MEDICINE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM; NEUROPROTECTIVE AGENTS; PROTEOMICS; RISK ASSESSMENT;

EID: 73949109875     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509357355     Document Type: Review

References (46)

1. Polman CH, Reingold SC, Barkhof F., et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology 2008 ; 70: 1134-1140.
2. Wiendl H., Hohlfeld R. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. Neurology 2009 ; 72: 1008-1015.
3. Wiendl H., Toyka KV, Rieckmann P., et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008 ; 255: 1449-1463.
4. Hohlfeld R. Multiple sclerosis: human model for EAE? Eur J Immunol 2009 ; 39: 2036-2039.
5. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006 ; 129: 1953-1971.
6. Krishnamoorthy G., Wekerle H. EAE: An immunologists magic eye. Eur J Immunol 2009 ; 39: 2031-2035.
7. Ben-Nun A., Wekerle H., Cohen IR The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981 ; 11: 195-199.
8. Flãgel A., Willem M., Berkowicz T., et al. Gene transfer into CD4+ T lymphocytes: green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses. Nat Med 1999 ; 5: 843-847.
9. Bartholomaus I., Kawakami N., Odoardi F., et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009 ; 462: 94-98.
10. http://www.nature.com/nature/journal/v462/n7269/ extref/nature08478-s6. mov.
11. Misgeld T., Kerschensteiner M. Neuroimaging: In vivo imaging of the diseased nervous system. Nature Rev Neurosci 2006 ; 7: 449-463.
12. Pollinger B., Krishnamoorthy G., Berer K., et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med 2009 ; 206: 1303-1316.
13. http://jem.rupress.org/cgi/content/full/jem.20090299/DC1.
14. Korn T., Bettelli E., Oukka M., et al. IL-17 and Th17 Cells. Annu Rev Immunol 2009 ; 27: 485-517.
15. Lock C., Hermans G., Pedotti R., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nature Med 2002 ; 8: 500-508.
16. Han MH, Hwang S. -I, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008 ; 451: 1076-1082.
17. Chabas D., Baranzini SE, Mitchell D., et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001 ; 294: 1731-1735.
18. Platten M., Youssef S., Hur EM, et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci U S A 2009 ; 106: 14948-14953.
19. Dornmair K., Goebels N., Weltzien HU, et al. T-cell-mediated autoimmunity - Novel techniques to characterize autoreactive T-cell receptors. Am J Pathol 2003 ; 163: 1215-1226.
20. Junker A., Ivanidze J., Malotka J., et al. Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain 2007 ; 130: 2789-2799.
21. Seitz S., Schneider CK, Malotka J., et al. Reconstitution of paired T cell receptor β±- and β2-chains from microdissected single cells of human inflammatory tissues. Proc Natl Acad Sci U S A 2006 ; 103: 12057-12062.
22. Gregersen JW, Holmes S., Fugger L. Humanized animal models for autoimmune diseases. Tiss Antigens 2004 ; 63: 383-394.
23. Ferguson B., Matyszak MK, Esiri MM, et al. Axonal damage in acute multiple sclerosis lesions. Brain 1997 ; 120: 393-399.
24. Trapp BD, Peterson J., Ransohoff RM, et al. Axonal transection in the lesion of multiple sclerosis. N Engl J Med 1998 ; 338: 278-285.
25. Kuhlmann T., Lingfeld T., BitschA, et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002 ; 125: 2202-2212.
26. Frischer JM, Bramow S., Dal-Bianco A., et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009 ; 135: 1175-1189.
27. Hohlfeld R., Kerschensteiner M., Meinl E. Dual role of inflammation in CNS disease. Neurology 2007 ; 68: S58 - S63.
28. Kerschensteiner M., Stadelmann C., Dechant G., et al. Neurotrophic cross-talk between the nervous and immune systems: Implications for neurological diseases. Ann Neurol 2003 ; 53: 292-304.
29. Kerschensteiner M., Gallmeier E., Behrens L., et al. Activated human T cells, B cells and monocytes produce brain-derived neurotrophic factor (BDNF) in vitro and in brain lesions: A neuroprotective role of inflammation? J Exp Med 1999 ; 189: 865-870.
30. Stadelmann C., Kerschensteiner M., Misgeld T., et al. BDNF and gp145trkB in multiple sclerosis brain lesions: Neuroprotective interactions between immune and neuronal cells? Brain 2002 ; 125: 75-85.
31. Sobottka B., Harrer MD, Ziegler U., et al. Collateral bystander damage by myelin-directed CD8+ T cells causes axonal loss. Am J Pathol 2009 ; 175: 1160-1166.
32. Trapp BD, Stys PK Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009 ; 8: 280-291.
33. Zipp F., Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 2006 ; 29: 518-527.
34. Mathey EK, Derfuss T., Storch MK, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007 ; 204: 2363-2372.
35. Bielekova B., Martin R. Development of biomarkers in multiple sclerosis. Brain 2004 ; 127: 1463-1478.
36. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004 ; 364: 2106-2112.
37. Bradl M., Misu T., Takahashi, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009 ; 66: 630-343.
38. Bennett JL, Lam C., Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009 ; 66: 617-629.
39. Kinoshita M., Nakatsuji Y., Kimura T., et al. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 2009 ; 386: 623-627.
40. Linington C., Bradl M., Lassmann H., et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988 ; 130: 443-454.
41. Schluesener HJ, Sobel RA, Linington C., et al. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 1987 ; 139: 4016-4021.
42. De Jager PL, Chibnik LB, Cui J., et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol 2009 ; 8: 1111-1119.
43. Kãmpfel T., Hohlfeld R. Multiple sclerosis. TNFRSF1A, TRAPS and multiple sclerosis. Nat Rev Neurol 2009 ; 5: 528-529.
44. De Jager PL, Jia X., Wang J., et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009 ; 41: 776-782.
45. Kãmpfel T., Hoffmann LA, Rubsamen H., et al. Late-onset tumor necrosis factor receptor-associated periodic syndrome in multiple sclerosis patients carrying the TNFRSF1A R92Q mutation. Arthritis Rheum 2007 ; 56: 2774-2783.
46. Kãmpfel T., Hoffmann LA, Pellkofer H., et al. Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases. Neurology 2008 ; 71: 1812-1820.